PTPN11 mutation manifesting as LEOPARD syndrome associated with hypertrophic plexi and neuropathic pain

Complete pain relief after bevacizumab in a patient with neurofibromatosis type 2

(2014) Attila Kollár et al.   ACTA ONCOLOGICA

The relaxation response resiliency program (3RP) in patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis: results from a pilot study

(2014) Ana-Maria Vranceanu et al.   JOURNAL OF NEURO-ONCOLOGY

Sirolimus Improves Pain in NF1 Patients With Severe Plexiform Neurofibromas

(2014) C. Hua et al.   PEDIATRICS

Sirolimus for non-progressive NF1-associated plexiform neurofibromas: An NF clinical trials consortium phase II study

(2013) Brian Weiss et al.   PEDIATRIC BLOOD & CANCER

The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches

(2012) Antonella De Luca et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy

(2012) Libero Santarpia et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Oral Ketamine in the Palliative Care Setting

(2011) Eliezer Soto et al.   American Journal of Hospice & Palliative Medicine

LEOPARD syndrome (PTPN11, T468M) in three boys fulfilling neurofibromatosis type 1 clinical criteria

(2011) Atilano Carcavilla et al.   EUROPEAN JOURNAL OF PEDIATRICS

Disorders of dysregulated signal traffic through the RAS-MAPK pathway: phenotypic spectrum and molecular mechanisms

(2010) Marco Tartaglia et al.   Annals of the New York Academy of Sciences

EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision

(2010) N. Attal et al.   EUROPEAN JOURNAL OF NEUROLOGY